{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:30:53Z","timestamp":1780374653853,"version":"3.54.1"},"reference-count":56,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"2","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncology Practice"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:p> The checkpoint inhibitors nivolumab and pembrolizumab are principal treatment options for relapsed or refractory classic Hodgkin lymphoma. In patients who decline autologous stem-cell transplantation or who are unsuited for high-dose chemotherapy and subsequent autologous stem-cell transplantation because of comorbidities, the use of checkpoint inhibitors may improve overall survival and have a manageable side effect profile. This clinical review provides an evidence-based summary to guide practicing oncologists in the use of checkpoint inhibitors in relapsed or refractory classic Hodgkin lymphoma and includes checkpoint inhibitor efficacy and adverse effect profiles. We highlight the use of checkpoint inhibitors in the management of relapsed or refractory classic Hodgkin lymphoma in patients who are ineligible for an autologous stem-cell transplant with the goal of improving disease control while limiting adverse events. <\/jats:p>","DOI":"10.1200\/op.20.00771","type":"journal-article","created":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T22:22:56Z","timestamp":1610490176000},"page":"64-71","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":12,"title":["Checkpoint Inhibition Therapy in Transplant-Ineligible Relapsed or Refractory Classic Hodgkin Lymphoma"],"prefix":"10.1200","volume":"17","author":[{"given":"Samer A.","family":"Al-Hadidi","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Baylor College of Medicine, Houston, TX"},{"name":"Department of Lymphoma and Myeloma, the University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hun Ju","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, the University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"b1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21438"},{"key":"b2","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-017-0385-y"},{"key":"b3","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)92411-L"},{"key":"b4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08938-9"},{"key":"b5","volume-title":"Center for International Blood and Marrow Transplant, a contractor for the C.W. Bill Young Cell Transplantation Program operated through the U. S. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau. Number of Transplants by Year"},{"key":"b6","volume-title":"Center for Drug Evaluation and Research. Clinical review: Adcetris (Brentuximab Vedotin). Biologics License Application (BLA) 125388"},{"key":"b7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-699850"},{"key":"b8","volume-title":"Bristol-Myers Squibb: Opdivo (Nivolumab) Highlights of Prescribing Information"},{"key":"b9","volume-title":"KEYTRUDA\u00ae (pembrolizumab) for Injection, for Intravenous Use"},{"key":"b10","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30192-3"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1680"},{"key":"b12","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0545-2"},{"key":"b13","first-page":"67","volume":"35","author":"Chen R","year":"2017","journal-title":"Oncology"},{"key":"b14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1514296"},{"key":"b15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282780"},{"key":"b16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1942"},{"key":"b17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-610436"},{"key":"b18","doi-asserted-by":"publisher","DOI":"10.1038\/nature09754"},{"key":"b19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.4482"},{"key":"b20","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad7118"},{"key":"b21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-772632"},{"key":"b22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905680"},{"key":"b23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-770719"},{"key":"b24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-772681"},{"key":"b25","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.19.00258"},{"key":"b26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-388058"},{"key":"b27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.022"},{"key":"b28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"b29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-595801"},{"key":"b30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708984"},{"key":"b31","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-7-24"},{"key":"b32","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1654100"},{"key":"b33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087"},{"key":"b34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.0793"},{"key":"b35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3467"},{"key":"b36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1316"},{"key":"b37","volume-title":"Hodgkin Lymphoma (Version 2.2020)","author":"National Comprehensive Cancer Network"},{"key":"b38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8005"},{"key":"b39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-811224"},{"key":"b40","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000137"},{"key":"b41","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000401"},{"key":"b42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.3308"},{"key":"b43","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0363-1"},{"key":"b44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123163"},{"key":"b45","doi-asserted-by":"publisher","DOI":"10.1016\/j.canrad.2018.12.005"},{"key":"b46","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs629"},{"key":"b47","volume-title":"Management of Immunotherapy-Related Toxicities (Version 1.2020)","author":"National Comprehensive Cancer Network"},{"key":"b48","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.7268"},{"key":"b49","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0538"},{"key":"b50","first-page":"5","volume":"4","author":"Cheson BD","year":"2015","journal-title":"Chin Clin Oncol"},{"key":"b51","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2018.03.018"},{"key":"b52","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc1183"},{"key":"b53","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.227"},{"key":"b54","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-236"},{"key":"b55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.06.072"},{"key":"b56","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718528"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP.20.00771","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T10:19:25Z","timestamp":1653819565000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP.20.00771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1200\/OP.20.00771"],"URL":"https:\/\/doi.org\/10.1200\/op.20.00771","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"2020-08-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}